Who founded Semarion - company?

Semarion - company was founded by Jeroen Verheyen, Tarun Vemulkar in 2018.

Who are Semarion - company's investors?

Semarion - company's investors include The FSE Group, Cambridge Capital Group, Found Capital, Start Codon, EMV Capital, Martlet Capital, Parkwalk Advisors.

Where is Semarion - company headquartered?

Semarion - company is headquartered in Cambridge, GB.

Semarion - company

Cambridge, GB · Founded 2018 · 14 employees on LinkedIn · 7 known investors

Find your way into Semarion - company

1,248 people in our graph share verified history with the Semarion - company team — schools, employers, funds. One of them is your warm intro.

Rahul Thayyalamkandyunlockedknows Tarun Vemulkar · together at Micron (overlapped)

×3knows the team · via European Commission

knows the team · via Universiteit Gent

×6knows the team · via Katholieke Universiteit Leuven

knows the team · via Technische Universität Dresden

Semarion is a University of Cambridge spin-out developing the SemaCyte platform, which converts adherent cells into barcoded, ready-to-use reagents for accelerated drug discovery and cell-based research. The platform combines materials engineering and cell biology to enable researchers to multiplex cell models and increase throughput in pharmaceutical assays.

Biotech Deep Tech Medical Devices New Materials SaaS

Founders & leadership

Semarion - company was founded in 2018 by Jeroen Verheyen and Tarun Vemulkar.

Jeroen Verheyen CEO and Co-FounderJeroen Verheyen holds degrees in Biomedical Sciences and Nanotechnology (both MSc, Magna Cum Laude) and has conducted research across diagnostics, stem cell therapy, drug delivery, nanomaterials, and biosensors. He is CEO and Co-Founder of Semarion, a University of Cambridge spin-out developing a microcarrier platform that converts adherent cells into reagents for drug discovery.

Tarun Vemulkar Co-founder & CTOTarun Vemulkar is Co-founder and CTO of Semarion, a University of Cambridge spin-out developing cell-based reagents for drug discovery. He has previously worked on microchip fabrication processes in industry and completed doctoral research in nanomagnetic therapy approaches.

Investors · 7

The FSE Group✓ confirmed by Semarion - companyFleet · $25K – $5M

How we know: the company's own site · The FSE Group's portfolio page · Not right? Tell us

Cambridge Capital Group✓ confirmed by Semarion - companyCambridge · $10K – $2M

How we know: the company's own site · Not right? Tell us

Found Capital✓ confirmed by Semarion - companyLondon

How we know: the company's own site · Not right? Tell us

Start Codon✓ confirmed by Semarion - companyCambridge

How we know: the company's own site · Not right? Tell us

EMV Capitallisted by EMV CapitalLondon

How we know: EMV Capital's portfolio page · Not right? Tell us

Martlet Capitallisted by Martlet CapitalCambridge · $317.5K

How we know: Martlet Capital's portfolio page · Not right? Tell us

Parkwalk AdvisorsreportedLondon

How we know: a partner's Signal profile · Not right? Tell us

Frequently asked questions

What does Semarion - company do?: Semarion is a University of Cambridge spin-out developing the SemaCyte platform, which converts adherent cells into barcoded, ready-to-use reagents for accelerated drug discovery and cell-based research. The platform combines materials engineering and cell biology to enable researchers to multiplex cell models and increase throughput in pharmaceutical assays.
Who founded Semarion - company?: Semarion - company was founded by Jeroen Verheyen, Tarun Vemulkar in 2018.
Who are Semarion - company's investors?: Semarion - company's investors include The FSE Group, Cambridge Capital Group, Found Capital, Start Codon, EMV Capital, Martlet Capital, Parkwalk Advisors.
Where is Semarion - company headquartered?: Semarion - company is headquartered in Cambridge, GB.